|
Atea Pharmaceuticals Inc (NASDAQ: AVIR) |
|
Atea Pharmaceuticals Inc
AVIR's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Atea Pharmaceuticals Inc 's sales fell
in II. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 5.17 %
Atea Pharmaceuticals Inc net loss increased from $-28 millions, to $-41 millions in II. Quarter 2024,
• More on AVIR's Growth
|
|
Atea Pharmaceuticals Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 8.51 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.
• More on AVIR's Valuation
|
|
|
|
|
Atea Pharmaceuticals Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 8.51 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.
Atea Pharmaceuticals Inc Price to Book Ratio is at 0.53 lower than Industry Avg. of 88.81. and higher than S&P 500 Avg. of 0.02
• More on AVIR's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com